NCT03819153: A reported trial by Novo Nordisk A/S
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03819153 |
|---|---|
| Title | Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in Subjects With Type 2 Diabetes and Chronic Kidney Disease |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 17, 2019 |
| Completion date | Jan. 9, 2024 |
| Required reporting date | Jan. 8, 2025, midnight |
| Actual reporting date | Jan. 5, 2025 |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |